Literature DB >> 17628024

Prostate cancer: palliative care and pain relief.

J C Thompson1, J Wood, D Feuer.   

Abstract

Introduction Metastatic prostate cancer is incurable and causes significant morbidity. The focus of treatment should be on improving quality of life through appropriate oncological treatment and palliative care. The National Institute for Clinical Excellence guidelines for urological cancer recommends palliative care for all patients with prostate cancer, according to need. This paper outlines the principles of modern palliative care in patients with metastatic prostate cancer within the UK. Discussion We highlight the main physical symptoms encountered in metastatic prostate cancer and their management. We also introduce the UK Department of Health's 'End-of-Life Care Programme'. This initiative intends to improve the lives and deaths of all patients with incurable disease and should be a priority for all health care professionals, within any setting. Conclusion Clearly, we have addressed the management of metastatic prostate cancer within the UK setting, though any of these government initiatives may provide a resource and framework in other countries.

Entities:  

Mesh:

Year:  2007        PMID: 17628024     DOI: 10.1093/bmb/ldm018

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  7 in total

1.  Prostate cancer pain management: EAU guidelines on pain management.

Authors:  Pia Bader; Dieter Echtle; Valerie Fonteyne; Kostas Livadas; Gert De Meerleer; Alvaro Paez Borda; Eleni G Papaioannou; Jan H Vranken
Journal:  World J Urol       Date:  2012-02-09       Impact factor: 4.226

2.  The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells.

Authors:  Patricia Adamo; Sean Porazinski; Shavanthi Rajatileka; Samantha Jumbe; Rachel Hagen; Man-Kim Cheung; Ian Wilson; Michael R Ladomery
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

3.  Longitudinal analysis of pain in patients with metastatic prostate cancer using natural language processing of medical record text.

Authors:  Norris H Heintzelman; Robert J Taylor; Lone Simonsen; Roger Lustig; Doug Anderko; Jennifer A Haythornthwaite; Lois C Childs; George Steven Bova
Journal:  J Am Med Inform Assoc       Date:  2012-11-09       Impact factor: 4.497

4.  Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial.

Authors:  D Cella; C Ivanescu; S Holmstrom; C N Bui; J Spalding; K Fizazi
Journal:  Ann Oncol       Date:  2014-10-30       Impact factor: 32.976

5.  Phase of care prevalence for prostate cancer in New South Wales, Australia: A population-based modelling study.

Authors:  Xue Qin Yu; Qingwei Luo; David P Smith; Mark S Clements; Manish I Patel; Dianne L O'Connell
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

6.  Equal receipt of specialized palliative care in breast and prostate cancer: a register study.

Authors:  Jenny Bergqvist; Christel Hedman; Torbjörn Schultz; Peter Strang
Journal:  Support Care Cancer       Date:  2022-06-14       Impact factor: 3.359

7.  Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy.

Authors:  Basetti Madhu; Greg L Shaw; Anne Y Warren; David E Neal; John R Griffiths
Journal:  Metabolomics       Date:  2016-06-30       Impact factor: 4.290

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.